<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151191">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01693289</url>
  </required_header>
  <id_info>
    <org_study_id>elsharkwy t</org_study_id>
    <nct_id>NCT01693289</nct_id>
  </id_info>
  <brief_title>Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome</brief_title>
  <official_title>Phase 1 Study of Efficacy of Combined Metformin-letrozole in Comparison With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <authority>Egypt:Zagazig University</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study compare the hormonal-metabolic and reproductive outcome between combined
      metformin-letrozole and ovarian drilling in clomiphene resistant women with polycystic
      syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>hormonal and metabolic changes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>reproductive outcome</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Focus of Study</condition>
  <arm_group>
    <arm_group_label>Metformin plus letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ovarian drilling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bilateral diathermy ovarian drilling, four drills each ovary</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin plus letrozole</intervention_name>
    <arm_group_label>Metformin plus letrozole</arm_group_label>
    <other_name>cidophage plus fumara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ovarian drilling</intervention_name>
    <arm_group_label>ovarian drilling</arm_group_label>
    <other_name>ovarian dithermy drilling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  polycystic ovary syndrome

          -  infertility

          -  clomiphene citrate resistance

        Exclusion Criteria:

          -  women with other causes of infertility as male factor or tubal factor, those with
             endocrine disorders as thyroid dysfunction and hyperprolactinemia women who received
             hormonal treatment or ovulation induction drugs 3 months prior to the study

          -  pregnancy during follow up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 25, 2012</lastchanged_date>
  <firstreceived_date>September 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>IBRAHIM ABD ELGAFOR</investigator_full_name>
    <investigator_title>obstetrics and gynecology department</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>letrozole</keyword>
  <keyword>ovarian drilling</keyword>
  <keyword>clomiphene resistance</keyword>
  <keyword>polycystic ovary.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
